What Societal CDMO does

Societal CDMO Inc. is a U.S.-based pharmaceutical contract development and manufacturing organization (CDMO) headquartered in Gainesville, Florida, with operations across three domestic sites in Oregon, Georgia, and Florida. The company provides integrated formulation development, analytical, and manufacturing services spanning the full drug product lifecycle from preclinical formulation through commercial supply, with explicit capabilities in oral bioavailability enhancement, multiparticulates, modified release, oral solids and liquids, dry powders for inhalation, topicals, cGMP clinical manufacturing, commercial manufacturing, technology transfer, packaging, and quality and compliance.

The underlying technology centers on pharmaceutical finished product formulation science, including spray drying, particle engineering, and complex oral dosage form design, supported by preformulation studies, process design, analytical method development, and stability programs. The service architecture is presented as an integrated platform linking design, development, and manufacturing rather than discrete stand-alone modules, with quality and compliance infrastructure embedded throughout to meet cGMP and global regulatory requirements.

The business model is a project- and contract-based CDMO revenue model, monetizing formulation development, clinical manufacturing, and commercial manufacturing services for pharmaceutical clients. Pricing is not publicly disclosed. The company was founded in 1982, employs 101-250 people, and was acquired by CoreRx, Inc. in April 2024 for $130 million, after which it has operated as a subsidiary within CoreRx's CDMO platform, currently doing business as Bend Bioscience. No named customer logos are publicly disclosed in the available sources.

Name

Societal CDMO

Legal name

Societal CDMO Inc.

Website

https://societalcdmo.com

Company type

Private

Founded year

1982

Operating status

Acquired

Headcount range

101–250 employees

Short description

Societal CDMO (operating as Bend Bioscience) is a U.S. pharmaceutical CDMO offering integrated formulation development, analytical, and cGMP manufacturing services across oral, inhalation, and topical dosage forms for pharmaceutical clients. The company operates from three U.S. sites and is a subsidiary of CoreRx, Inc.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Development and Manufacturing (CDMO)

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

akta.pro secondary industries

Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Packaging, Labeling & Serialization (Clinical/Commercial) CDMO (HLAGABAJ)

Keywords

• Pharmaceutical CDMO services
• Contract drug manufacturing
• Formulation development
• Oral solid dosage
• CGMP clinical manufacturing

Headquarters

HQ city

Gainesville

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Core offering

Societal CDMO (operating under the Bend Bioscience brand) is a pharmaceutical finished product contract development and manufacturing organization (CDMO) offering integrated services across the drug development lifecycle from early-stage design through commercial supply. The company provides formulation development for oral solids, oral liquids, multiparticulates, modified release, dry powder inhalation, and topicals, supported by preformulation, analytical and stability testing, cGMP clinical and commercial manufacturing, technology transfer, packaging, and quality and regulatory compliance services.

Product overview

Bend Bioscience operates as a pharmaceutical finished product CDMO (Contract Development and Manufacturing Organization) offering integrated services across the drug development lifecycle from design through commercial manufacturing. The company provides a comprehensive portfolio of formulation development services including Oral Bioavailability Enhancement, Multiparticulates, Modified Release, Oral Dosage Form Design, Oral Solids, Oral Liquids, Powders for Inhalation, and Topicals. These formulation capabilities are complemented by manufacturing services (cGMP Clinical Manufacturing, Commercial Manufacturing), technology transfer, packaging, and analytical & stability testing. The service architecture follows a unified platform model where preformulation, analytical development, manufacturing, and quality compliance work together as an integrated offering rather than as separate modules.

Differentiator

Problem solved

Functional benefit

Products and services

• Oral Bioavailability Enhancement Specialized formulation service focused on improving the oral bioavailability of drug compounds through advanced scientific techniques, intended for pharmaceutical sponsors developing oral drugs with poor bioavailability.
• Multiparticulates Drug delivery service involving development and manufacturing of multiparticulates for controlled release and targeted delivery applications, for sponsors needing tailored multiparticulate dosage forms.
• Modified Release Formulation development service for modified release dosage forms that control drug release timing and rate, for sponsors requiring extended, delayed, or otherwise modified release profiles.
• Oral Dosage Form Design (OSD) Comprehensive oral solid dosage form design and development service covering tablets, capsules, and related formulations, for sponsors developing oral solid drug products.
• Oral Solids Manufacturing service for oral solid dosage forms including tablets and capsules for clinical and commercial production, intended for pharmaceutical sponsors needing cGMP oral solid supply.
• Oral Liquids Formulation and manufacturing service for oral liquid dosage forms including solutions, suspensions, and syrups, for sponsors developing oral liquid drug products.
• Powders for Inhalation Specialized manufacturing service for dry powder inhalation products requiring precise particle engineering and delivery systems, for sponsors developing inhaled therapies.
• Topicals Formulation and manufacturing service for topical drug products including creams, ointments, gels, and lotions, for sponsors developing topical pharmaceutical products.
• Preformulation & Process Design Early-stage development service encompassing preformulation studies and process design to establish robust manufacturing parameters for pharmaceutical sponsors in early development.
• Analytical & Stability Comprehensive analytical testing and stability studies service to support drug development and regulatory submissions, for sponsors requiring method development and stability data packages.
• cGMP Clinical Manufacturing Clinical trial material manufacturing service compliant with current Good Manufacturing Practice regulations for early-phase clinical supplies, intended for pharmaceutical sponsors running clinical trials.
• Commercial Manufacturing Large-scale commercial drug product manufacturing service for global market supply, intended for pharmaceutical sponsors commercializing approved drug products.
• Technology Transfer Service facilitating the transfer of manufacturing processes and analytical methods from client facilities to Societal CDMO manufacturing sites, for sponsors transitioning production to the CDMO.
• Packaging Drug product packaging service including primary and secondary packaging for clinical and commercial supplies, for pharmaceutical sponsors needing finished packaged product.
• Quality & Compliance Quality assurance and regulatory compliance service ensuring adherence to cGMP and global regulatory requirements, supporting pharmaceutical sponsors through quality oversight and compliance management.

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• CoreRx, Inc.coreStrategic or Co-development Partner · 1 April 2024In April 2024, CoreRx, Inc. acquired Societal CDMO Inc. for $130 million to expand its formulation development and scale-up manufacturing capabilities. This acquisition strengthened CoreRx's position in the CDMO market by adding Societal CDMO's expertise in complex drug formulations and manufacturing scale-up services.

Scale indicators1 record

Recent moves6 records

Expansion highlights4 records

Direct peers

• CoreRx: Direct strategic acquirer/parent of Societal CDMO; provides formulation development and small-batch manufacturing services, overlapping with Societal's preformulation and clinical supply capabilities.
• Aenova Group: European-headquartered CDMO specializing in solid oral dosage forms, including modified release and complex formulations; directly comparable to Societal's core drug product CDMO model.
• Hovione: Specialty CDMO with strong capabilities in particle engineering, amorphous solid dispersions, and inhalation; overlaps directly with Societal's bioavailability enhancement and inhalation offerings.
• Alcami Corporation: U.S. CDMO offering formulation development, analytical services, and clinical/commercial manufacturing for oral solids and sterile products; competes with Societal in early-phase drug product development.
• Metrics Contract Services: U.S.-based CDMO focused on oral solid dose formulation, clinical supply, and small-batch commercial manufacturing; closely comparable in scale and service mix to Societal CDMO.
• Particle Sciences (Lubrizol Life Science): Specialty CDMO focused on complex drug delivery, including particulate and modified release systems, with strong bioavailability enhancement capabilities comparable to Societal's high-science offerings.

Broad incumbents

• Patheon (PCI Pharma Services): One of the largest global CDMOs offering integrated drug product development, clinical and commercial manufacturing across oral solids, sterile, and specialty formats; a key scale competitor for Societal's commercial manufacturing work.
• Catalent: Global CDMO leader offering softgel, oral solid, inhalation, and biologics services with extensive commercial-scale capacity; competes with Societal across oral solids, modified release, and inhalation niches.
• Cambrex: CDMO with API and finished dosage form capabilities, including oral solids; competes for early development and commercial manufacturing programs comparable to Societal's services.

Emerging players

• Ascendia Pharmaceuticals: Emerging specialty CDMO focused on complex injectable and poorly soluble oral formulations; overlaps with Societal in bioavailability and modified release niches.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/societalcdmo

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Societal CDMO